Emergent BioSolutions (EBS -1.9%) and Integrated BioTherapeutics enter into a joint research, development and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Under the partnership, Integrated Bio extends an exclusive global license to its proprietary vaccine antigens and know-how to EBS. Financial terms are not disclosed.
Learn what the corporates are thinking.
This webinar series highlights the technical and scouting needs of our Corporate Selection Committee for the University Startups Conference and Demo Day. Each session will feature speakers from open innovation, corporate venture, and R&D to talk about what they are looking for from universities and startups, and partners in the investment community.
Gaitherburg-based OpGen Inc. has entered a new partnership with pharmaceutical giant Merck & Co. in a collaboration officials say will help more quickly combat so-called superbugs with rapid diagnostic tests.
OpGen, which has focused on creating rapid DNA diagnostic tools to improve antibiotic decision-making, has been building a bank of bacterial pathogens to offer more accurate infection diagnostic testing.
The Tech Council of Maryland is pleased to announce their new chairman and recently named board members representing a diverse coalition of Maryland technology, life sciences, legal and academic professionals.
Incoming Chairman Rene B. LaVigne has over 25 years of sales, marketing, operations, finance and accounting experience in the information technology and financial industries. He also serves as President and Chief Executive of Iron Bow Technologies.
When historians look back at the presidential election of 2016 they will certainly have many questions, but perhaps the biggest one isn’t getting enough attention today. “What the (insert the popular profanity of the future)?” they will likely ask. “Why was there hardly any mention of climate change?” Or will the future inhabitants of Earth be so distracted by survival that they won’t even care what happened in 2016 when the greatest country on the planet at that time denied this problem existed?
Building Specifications:
Relevant Health alumni, Agewell Biometrics is in the running to win the Medstartr Open Crowd Challenge. You can suppoprt them and help end the epidemic of avoidable falls in the elderly. Make a tax deductable donation or show your support by ‘Liking’ the campaign and help Agewell over the finish line.
Agewell’s Equilibrium™ platform is the first automated, fall prevention system. Using a smartphone, and soon a wearable sensor, Equilibrium™ measures strength, balance and physical function in order to identify fall risk, giving an early window of opportunity to take the right preventative steps before a fall happens.
One in three people aged 65 years and older fall every year – the leading cause of injury-related deaths amongst older adults, in addition to causing loss of independence, social isolation and depression. As many as 50% of these falls could be prevented with simple exercises, but only once a problem is identified. Equilibrium™ gives you the early warning for fall risk and soon you’ll be able to download it on your iOS or Android phone as a simple-to-use app.
Thursday, December 1, 2016 | 6:00 – 8:30 p.m.
The more than 25 Showcase companies are some of the best from the robust U.S.-Israel Business ecosystem in fields including cyber security, homeland security, bio/pharma, environmental, healthcare, medical device and software. For more information on the companies, go to MarylandIsrael.org/showcase2016.
The mosquito-borne Zika virus — described in recent, grim federal warnings as “not controllable by current technologies”— could become an important source of hope for a regrouped Novavax Inc.
Gaithersburg-based Novavax (NASDAQ: NVAX), still recovering from stunning negative results from its phase 3 trials of its lead respiratory syncytial virus (RSV) vaccine for older adults, said this week that it had “exciting preclinical data” from its new Zika program.
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (GEN), showed that Trump’s presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a “brain drain” as foreign-born researchers educated in American universities will be more likely to leave.
